|
Avandia Hearing Reveals Fundamental Flaws at FDA
Union of Concerned Scientists The advisory panel met yesterday and today to review safety questions regarding Avandia, a GlaxoSmithKline diabetes drug that has been linked to heart … Avandia: The Key Vote Is Negative Close the FDA Approval Gap Whistleblower News Roundup 7.15.10 |
|
Panel Doesn't Recommend Pulling Avandia
OzarksFirst.com (blog) The FDA was hoping to end the debate over whether Avandia was too dangerous to sell to diabetics. The drug has been under fire since 2007 when the first … The Avandia Controversy Avandia's Sales Drop Far Behind Actos Avandia decision could bolster rivals' sales |
 Washington Post |
Patients taking Avandia should keep on doing so, doctor groups say
Los Angeles Times Diabetics taking Avandia who are concerned about the drug following Wednesday's decision by a Food and Drug … Don't dump Avandia, diabetes groups urge patients Avandia may be restricted. Now what to do? Concerned about Avandia? Here are other options |
 TheBull.com.au |
European shares tumble, economy concerns persist
Reuters L) added 1.8 percent in a relief rally after a US panel of health experts voted to keep the drugmaker's diabetes pill Avandia on the market but with new … European stocks resume rally after JPMorgan results European stocks dip; eyes on JPMorgan results Closing stock market indices outside the US |
 The Guardian |
Glaxo's Shares Rise on Improved Outlook
New York Times (blog) The British company took a public beating Wednesday in a split vote by a Food and Drug Administration advisory committee over the diabetes drug Avandia. … Glaxo To Book GBP1.57B To Settle Litigation, Including Avandia Glaxo takes $2.4 bln charge, Avandia mostly settled Glaxo To Take $2.4 Billion Charge To Cover Avandia Cases, Other Legal Woes |